GlassScriptPhysician profile
Cassandra M Bittenbender
NPI 1407848757
$13,391.67
in general payments reported to CMS, 2019-2025
47 companies · $2,196 in 2025
The $2,196 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,684 · 2020: $1,549 · 2021: $2,475 · 2022: $2,028 · 2023: $1,722 · 2024: $1,738 · 2025: $2,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,655.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,677.73 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,171.38 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,017.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $917.28 | 2019-2025 | |
| Glaxosmithkline, LLC. | $800.64 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $766.99 | 2019-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $711.29 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.94 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $430.88 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Allergan, INC. | $427.59 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $358.92 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $266.66 | 2019-2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $261.54 | 2019-2025 | |
| Astellas Pharma US INC | $245.26 | 2019-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $244.74 | 2022-2025 | Caplyta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Bittenbender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.